SCHEDULE: Todd Morrison Boosts Stake in BioRestorative Therapies

Todd Hale Morrison has increased his beneficial ownership in BioRestorative Therapies, Inc. to 7.7% of common stock.

Summary

• Todd Hale Morrison, a U.S. citizen, reported beneficial ownership of 685,000 shares of BioRestorative Therapies, Inc. common stock.
• This ownership represents approximately 7.7% of the outstanding shares of the Issuer's Common Stock.
• The percentage was calculated based on 8,876,242 shares of common stock outstanding as of November 12, 2025, as reported in the Issuer's Form 424B3.
• Morrison holds shared voting power and shared dispositive power over all 685,000 shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. An individual increasing their stake to a significant percentage (7.7%) suggests confidence in the company's future, although the filing itself is passive and does not indicate an intent to influence control.

Positives

• A significant individual, Todd Hale Morrison, has increased his beneficial ownership to 7.7%, which can be interpreted as a vote of confidence in BioRestorative Therapies, Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance from the company.

Industry Context

BioRestorative Therapies, Inc. operates in the biotechnology sector, focusing on regenerative medicine. Significant individual ownership updates like this Schedule 13G filing are common in the industry and are closely watched by investors for signals of confidence or potential strategic interest.

Stakeholder Impact

• Shareholders may view the increased beneficial ownership by Todd Hale Morrison as a positive signal, potentially indicating a belief in the company's long-term value and prospects.

Key Dates

Recommendation

The increased beneficial ownership by Todd Hale Morrison to 7.7% is a positive indicator, suggesting confidence in BioRestorative Therapies. However, as a Schedule 13G filing, it represents a passive investment without stated intent to influence control or operations. While it provides a favorable signal, it does not present new operational or financial data to warrant a 'buy' or 'sell' recommendation. Existing investors might consider this a reinforcing factor to 'hold' their positions, awaiting further company-specific developments.

Keywords

BioRestorative Therapies, BRTX, Todd Morrison, Schedule 13G, beneficial ownership, common stock, biotechnology